Dennis Cho Sells 316 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) insider Dennis Cho sold 316 shares of Twist Bioscience stock in a transaction on Friday, December 20th. The stock was sold at an average price of $44.90, for a total value of $14,188.40. Following the sale, the insider now directly owns 113,171 shares of the company’s stock, valued at $5,081,377.90. This represents a 0.28 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Dennis Cho also recently made the following trade(s):

• On Monday, December 16th, Dennis Cho sold 133 shares of Twist Bioscience stock. The stock was sold at an average price of $46.81, for a total transaction of $6,225.73.
• On Friday, December 6th, Dennis Cho sold 367 shares of Twist Bioscience stock. The shares were sold at an average price of $52.70, for a total transaction of $19,340.90.
• On Monday, November 11th, Dennis Cho sold 1,507 shares of Twist Bioscience stock. The stock was sold at an average price of $48.00, for a total transaction of $72,336.00.
• On Monday, November 4th, Dennis Cho sold 659 shares of Twist Bioscience stock. The stock was sold at an average price of $41.56, for a total value of $27,388.04.
• On Wednesday, October 2nd, Dennis Cho sold 3,104 shares of Twist Bioscience stock. The shares were sold at an average price of $43.21, for a total value of $134,123.84.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $48.17 on Friday. Twist Bioscience Co. has a 52-week low of $27.41 and a 52-week high of $60.90. The company has a fifty day moving average of $45.61 and a 200-day moving average of $46.72. The company has a market capitalization of $2.86 billion, a PE ratio of -13.38 and a beta of 1.82.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Robert W. Baird raised their target price on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Wolfe Research initiated coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. TD Cowen reiterated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. Finally, Scotiabank boosted their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the company a “sector outperform” rating in a research report on Tuesday, November 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus price target of $51.90.

Institutional Trading of Twist Bioscience

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Principal Financial Group Inc. increased its position in shares of Twist Bioscience by 210.2% during the second quarter. Principal Financial Group Inc. now owns 122,911 shares of the company’s stock worth $6,057,000 after buying an additional 83,287 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Twist Bioscience by 215.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after acquiring an additional 20,035 shares during the last quarter. Barclays PLC lifted its position in Twist Bioscience by 214.8% in the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares in the last quarter. FMR LLC boosted its stake in Twist Bioscience by 6.0% during the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after purchasing an additional 12,327 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in Twist Bioscience by 128.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after purchasing an additional 21,357 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.